vTv Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
VTVT$21.00-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for the Years Ended and
Consolidated Statements of Operations
(in thousands, except per share and share data)
| Years Ending December 31, | |||
|---|---|---|---|
| 2024 | 2023(*) | 2022(*) | |
| Revenue | $1,017 | $— | $2,018 |
| Operating expenses: | |||
| Research and development | 11,546 | 13,595 | 12,357 |
| General and administrative | 13,651 | 11,907 | 12,201 |
| Total operating expenses | 25,197 | 25,502 | 24,558 |
| Operating loss | (24,180) | (25,502) | (22,540) |
| Other income (expense), net | 160 | (1,497) | (3,616) |
| Other (expense) income – related party | (150) | 574 | 946 |
| Interest income | 1,565 | 472 | 352 |
| Interest expense | — | (13) | (15) |
| Loss before income taxes and noncontrolling interest | (22,605) | (25,966) | (24,873) |
| Income tax provision | 100 | — | 200 |
| Net loss before noncontrolling interest | (22,705) | (25,966) | (25,073) |
| Less: net loss attributable to noncontrolling interest | (4,243) | (5,716) | (5,909) |
| Net loss attributable to vTv Therapeutics Inc. | $(18,462) | $(20,250) | $(19,164) |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $(18,462) | $(20,250) | $(19,164) |
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $(3.20) | $(9.71) | $(9.98) |
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 5,771,052 | 2,084,973 | 1,919,788 |
| (*) Adjusted retroactively for reverse stock split | |||
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Class A Common Stock · Class B Common Stock | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RedeemableNoncontrollingInterest · Shares · Amount · Shares · Amount · AdditionalPaid-inCapital · Accumulated Deficit · Total vTv Therapeutics Inc Stockholders’ Equity (Deficit) · NoncontrollingInterest · Total Stockholders' Equity (Deficit) | ||||||||||||||||||||||||
| Balances at December 31, 2021 | $24,962 | 1,721,452 | $17 | 577,349 | $6 | $239,071 | $(248,834) | $(9,740) | $— | $(9,740) | ||||||||||||||
| Net loss | (5,909) | — | — | — | — | — | (19,164) | (19,164) | — | (19,164) | ||||||||||||||
| Share-based compensation | — | — | — | — | — | 1,272 | — | 1,272 | — | 1,272 | ||||||||||||||
| Issuance of Class A common stock to collaboration agreement, net of offering costs | — | 259,657 | 3 | — | — | 5,037 | — | 5,040 | — | 5,040 | ||||||||||||||
| Issuance of Class A common stock under CinRx purchase agreement, net of offering costs | — | 103,864 | 1 | — | — | 9,377 | — | 9,378 | — | 9,378 | ||||||||||||||
| Change in redemption value of noncontrolling interest | (2,474) | — | — | — | — | — | 2,474 | 2,474 | — | 2,474 | ||||||||||||||
| Balances at December 31, 2022 | 16,579 | 2,084,973 | 21 | 577,349 | 6 | 254,757 | (265,524) | (10,740) | — | (10,740) | ||||||||||||||
| Net loss | (5,716) | — | — | — | — | — | (20,250) | (20,250) | — | (20,250) | ||||||||||||||
| Share-based compensation | — | — | — | — | — | 1,578 | — | 1,578 | — | 1,578 | ||||||||||||||
| Change in redemption value of noncontrolling interest | (4,732) | — | — | — | — | — | 4,732 | 4,732 | 4,732 | |||||||||||||||
| Balances at December 31, 2023 | 6,131 | 2,084,973 | 21 | 577,349 | 6 | 256,335 | (281,042) | (24,680) | — | (24,680) | ||||||||||||||
| Net loss attributable to vTv Therapeutics Inc. | — | — | — | — | — | — | (18,462) | (18,462) | — | (18,462) | ||||||||||||||
| Net loss attributable to redeemable noncontrolling interest(*) | (1,085) | — | — | — | — | — | — | — | — | — | ||||||||||||||
| Change in redemption value of redeemable noncontrolling interest | 214 | — | — | — | — | — | (214) | (214) | — | (214) | ||||||||||||||
| Reclassification of redeemable noncontrolling interest to permanent equity (See Note 12) | (5,260) | — | — | — | — | — | — | — | 5,260 | 5,260 | ||||||||||||||
| Share-based compensation | — | — | — | — | — | 2,757 | — | 2,757 | — | 2,757 | ||||||||||||||
| Issuance of Class A common stock and pre-funded warrants, net offering costs | — | 347,884 | 3 | — | — | 50,332 | — | 50,335 | — | 50,335 | ||||||||||||||
| Issuance of Class A Common Stock under ATM offering | — | 179,400 | 2 | — | — | 2,461 | — | 2,463 | — | 2,463 | ||||||||||||||
| Net loss attributable to noncontrolling interest | — | — | — | — | — | — | — | — | (3,158) | (3,158) | ||||||||||||||
| Balances at December 31, 2024 | $— | 2,612,257 | $26 | 577,349 | $6 | $311,885 | $(299,718) | $12,199 | $2,102 | $14,301 | ||||||||||||||
| (*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 12) | ||||||||||||||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.